Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy

Table 2 Univariable and multivariable analyses of the first-line response to chemotherapy

Variables	Tumor response			Univariable Analysis		Multivariable analysis
Variables	CR + PR	SD + PD	ORR	OR (95% CI)	p value	OR (95% CI)	p value
Age (years)					0.042*		0.251
≤ 65	57	38	60.0%	Ref.		Ref.
>65	23	31	42.6%	0.495 (0.251–0.974)		0.593 (0.243–1.447)
Sex					0.177
Male	56	55	50.5%	0.594 (0.279–1.266)
Female	24	14	63.2%	Ref.
Smoking					0.550
Never	34	26	56.7%	Ref.
Ever	46	43	51.7%	0.818 (0.423–1.580)
ECOG PS					0.001**		0.302
0	49	24	67.1%	Ref.		Ref.
1	31	45	40.8%	0.337 (0.173–0.659)		0.646 (0.282–1.481)
Lesion type					0.344
Peripheral	41	30	57.7%	Ref.
Central	39	39	50.0%	0.732 (0.383–1.398)
Histological type					0.857
Adenocarcinoma	51	43	54.3%	Ref.
Squamous	29	26	52.7%	0.940 (0.483–1.832)
Clinical stage					0.004**		0.008**
IIIB	46	23	66.7%	Ref.		Ref.
IV	34	46	42.5%	0.370 (0.189–0.721)		0.283 (0.112–0.718)
CEA					0.042*		0.170
Normal	57	38	60.0%	Ref.		Ref.
Increased	23	31	42.6%	0.495 (0.251–0.974)		0.539 (0.223–1.303)
Albumin					0.093
Decreased	22	28	44.0%	0.555 (0.279–1.104)
Normal	58	41	58.6%	Ref.
WBC(×10⁹/L)					0.003**		0.424
≤ 7.8	53	29	64.6%	Ref.		Ref.
>7.8	27	40	40.3%	0.369 (0.190–0.719)		0.710 (0.307–1.644)
LMR					< 0.001***		< 0.001***
≤ 3.73	32	57	36.0%	0.140 (0.065–0.302)		0.167 (0.062–0.454)
>3.73	48	12	80.0%	Ref.		Ref.
NLR					0.009**		0.737
≤ 2.67	45	24	65.2%	Ref.		Ref.
>2.67	35	45	43.8%	0.415 (0.214–0.806)		1.176 (0.456–3.032)
PLR					0.084
≤ 164	54	37	59.3%	Ref.
>164	26	32	44.8%	0.557 (0.286–1.083)
SUVmax					< 0.001***		0.001**
≤ 11.6	50	19	72.5%	Ref.		Ref.
>11.6	30	50	37.5%	0.228 (0.114–0.457)		0.217 (0.090–0.525)

ECOG PS Eastern Cooperative Oncology Group Performance Status, CEA carcinoembryonic antigen, WBC white blood cell, LMR lymphocyte-monocyte ratio, NLR neutrophil-lymphocyte ratio, PLR platelet-lymphocyte ratio, SUVmax maximum standardized uptake value, CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate, OR odds ratio, CI confidence interval. *, p < 0.05; **, p < 0.01; ***, p < 0.001